Evidence map›Paper›PMID 34782464›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases.

Jin Kyeong Choi, Cheng-Rong Yu, So Jin Bing, Yingyos Jittayasothorn, Mary J Mattapallil, Minkyung Kang, Seung Bum Park, Hyun-Su Lee, Lijin Dong, Guangpu Shi and 2 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 66 citations in OpenAlex.

  1. B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Review
  4. Programmed death-ligand 1 on ex vivo-expanded toll-like-receptor-Bregs prevents allograft rejection by Breg viability promotion, CD4American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  5. A distinct TCRiScience · 2026
    Article
  6. Review
  7. The role and mechanism of IL‑35 in myasthenia gravis (Review).International journal of molecular medicine · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. The mCell death and differentiation · 2025
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Jin Kyeong ChoiMolecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), NIH, Bethesda, MD 20892.
Cheng-Rong YuMolecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), NIH, Bethesda, MD 20892.ORCID 0000-0001-7246-0362
So Jin BingImmunoregulation Section, Laboratory of Immunology, NEI, NIH, Bethesda, MD 20892.
Yingyos JittayasothornImmunoregulation Section, Laboratory of Immunology, NEI, NIH, Bethesda, MD 20892.
Mary J MattapallilImmunoregulation Section, Laboratory of Immunology, NEI, NIH, Bethesda, MD 20892.ORCID 0000-0003-0615-7343
Minkyung KangMolecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), NIH, Bethesda, MD 20892.
Seung Bum ParkLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD 20892.ORCID 0000-0003-2834-9071
Hyun-Su LeeMolecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), NIH, Bethesda, MD 20892.
Lijin DongNEI Genetic Engineering Core Facility, NEI, NIH, Bethesda, MD 20892.ORCID 0000-0001-7401-9511
Guangpu ShiNEI Genetic Engineering Core Facility, NEI, NIH, Bethesda, MD 20892.ORCID 0000-0002-0528-2030
Rachel R CaspiImmunoregulation Section, Laboratory of Immunology, NEI, NIH, Bethesda, MD 20892.
Charles E EgwuaguMolecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), NIH, Bethesda, MD 20892; egwuaguc@nih.gov.ORCID 0000-0002-9986-3839
National Eye Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Development of Immunologic therapies against uveitisZIAEY000350 · NEI · NATIONAL EYE INSTITUTE · PI EGWUAGU, CHARLES E · 2009 to 2025
$6.7M
Mechanisms of immune homeostasis and regulation of intraocular inflammationZIAEY000372 · NEI · NATIONAL EYE INSTITUTE · PI EGWUAGU, CHARLES E · 2009 to 2025
$6.5M
Intramural NIH HHS ZIA EY000350Intramural NIH HHS ZIA EY000372
6 · The paper itself

Abstract

Regulatory B cells (Breg cells) that secrete IL-10 or IL-35 (i35-Breg) play key roles in regulating immunity in tumor microenvironment or during autoimmune and infectious diseases. Thus, loss of Breg function is implicated in development of autoimmune diseases while aberrant elevation of Breg prevents sterilizing immunity, exacerbates infectious diseases, and promotes cancer metastasis. Breg cells identified thus far are largely antigen-specific and derive mainly from B2-lymphocyte lineage. Here, we describe an innate-like IL-27-producing natural regulatory B-1a cell (i27-Breg) in peritoneal cavity and human umbilical cord blood. i27-Bregs accumulate in CNS and lymphoid tissues during neuroinflammation and confers protection against CNS autoimmune disease. i27-Breg immunotherapy ameliorated encephalomyelitis and uveitis through up-regulation of inhibitory receptors (Lag3, PD-1), suppression of Th17/Th1 responses, and propagating inhibitory signals that convert conventional B cells to regulatory lymphocytes that secrete IL-10 and/or IL-35 in eye, brain, or spinal cord. Furthermore, i27-Breg proliferates in vivo and sustains IL-27 secretion in CNS and lymphoid tissues, a therapeutic advantage over administering biologics (IL-10, IL-35) that are rapidly cleared in vivo. Mutant mice lacking irf4 in B cells exhibit exaggerated increase of i27-Bregs with few i35-Bregs, while mice with loss of irf8 in B cells have abundance of i35-Bregs but defective in generating i27-Bregs, identifying IRF8/BATF and IRF4/BATF axis in skewing B cell differentiation toward i27-Breg and i35-Breg developmental programs, respectively. Consistent with its developmental origin, disease suppression by innate i27-Bregs is neither antigen-specific nor disease-specific, suggesting that i27-Breg would be effective immunotherapy for a wide spectrum of autoimmune diseases.

Indexed as

AnimalsAutoimmune DiseasesB-Lymphocytes, RegulatoryCell DifferentiationCentral Nervous System DiseasesEncephalitisInterferon Regulatory Factor-4Interferon Regulatory Factor-8Interferon Regulatory FactorsInterleukin-10Interleukin-27MiceNeuroinflammatory DiseasesUveitisIL10 protein, mouseInterferon Regulatory Factor-4Interferon Regulatory Factor-8Interferon Regulatory FactorsInterleukin-10Interleukin-27B-1a cellsCNS autoimmune diseasesi27-Breg cellsneuroinflammationuveitis and encephalitis

Identifiers

PMID34782464
PMCPMC8617509
OpenAlexW3213067309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.